Literature DB >> 24318356

The heterogeneity of ovarian cancer.

I Meinhold-Heerlein1, S Hauptmann.   

Abstract

Ovarian cancer carries the worst prognosis of all gynecological malignancies. This is mainly due to its resistance against commonly used cytostatic drugs as well as the lack of a screening method for its detection at an early stage. Both basic and translational research have shown over the past decades that ovarian cancer as a medical term includes several types of tumors with different phenotypes, molecular biology, etiology, tumor progression, and even different prognosis. In this issue of Archives of Gynecology and Obstetrics, J. Dietel presents a review article about novel findings of the etiopathogenesis of ovarian cancer and the role that fallopian tubes may play. He also outlines the implied clinical consequences. Here, we give a brief overview of the heterogeneity of ovarian cancer to introduce the topic.

Entities:  

Mesh:

Year:  2014        PMID: 24318356     DOI: 10.1007/s00404-013-3114-3

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  25 in total

1.  Ovarian Cancer Treatment Stratification Using Ex Vivo Drug Sensitivity Testing.

Authors:  Ines Lohse; Diana J Azzam; Hassan Al-Ali; Claude-Henry Volmar; Shaun P Brothers; Tan A Ince; Claes Wahlestedt
Journal:  Anticancer Res       Date:  2019-08       Impact factor: 2.480

2.  Human Leukocyte Antigen-Presented Macrophage Migration Inhibitory Factor Is a Surface Biomarker and Potential Therapeutic Target for Ovarian Cancer.

Authors:  Andrea M Patterson; Saghar Kaabinejadian; Curtis P McMurtrey; Wilfried Bardet; Ken W Jackson; Rosemary E Zuna; Sanam Husain; Gregory P Adams; Glen MacDonald; Rachelle L Dillon; Harold Ames; Rico Buchli; Oriana E Hawkins; Jon A Weidanz; William H Hildebrand
Journal:  Mol Cancer Ther       Date:  2015-12-30       Impact factor: 6.261

3.  Diagnostic Model of Serum miR-193a-5p, HE4 and CA125 Improves the Diagnostic Efficacy of Epithelium Ovarian Cancer.

Authors:  Xiaojuan Ren; Hui Zhang; Hui Cong; Xudong Wang; Hongbing Ni; Xianjuan Shen; Shaoqing Ju
Journal:  Pathol Oncol Res       Date:  2018-03-08       Impact factor: 3.201

4.  Heterogeneity of tumor chemosensitivity in ovarian epithelial cancer revealed using the adenosine triphosphate-tumor chemosensitivity assay.

Authors:  Jin Zhang; Hongxia Li
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

5.  Dual Targeting of mTOR Activity with Torin2 Potentiates Anticancer Effects of Cisplatin in Epithelial Ovarian Cancer.

Authors:  Azhar R Hussain; Maha Al-Romaizan; Maqbool Ahmed; Saravanan Thangavel; Fouad Al-Dayel; Shaham Beg; Shahab Uddin; Abdul K Siraj; Khawla S Al-Kuraya
Journal:  Mol Med       Date:  2015-05-26       Impact factor: 6.354

6.  Multiparameter Single-Cell Characterization of Ovarian Intratumor Heterogeneity.

Authors:  Kristin G Beaumont; Christina Andreou; Ethan Ellis; Robert Sebra
Journal:  Methods Mol Biol       Date:  2022

Review 7.  The Diagnostic and Prognostic Potential of microRNAs in Epithelial Ovarian Carcinoma.

Authors:  Priya Samuel; David Raul Francisco Carter
Journal:  Mol Diagn Ther       Date:  2017-02       Impact factor: 4.074

8.  Statement by the Kommission Ovar of the AGO: The New FIGO and WHO Classifications of Ovarian, Fallopian Tube and Primary Peritoneal Cancer.

Authors:  I Meinhold-Heerlein; C Fotopoulou; P Harter; C Kurzeder; A Mustea; P Wimberger; S Hauptmann; J Sehouli
Journal:  Geburtshilfe Frauenheilkd       Date:  2015-10       Impact factor: 2.915

9.  The Exocrine Differentiation and Proliferation Factor (EXDPF) Gene Promotes Ovarian Cancer Tumorigenesis by Up-Regulating DNA Replication Pathway.

Authors:  Yangjiong Xiao; Yunxin Lai; Yang Yu; Pengcheng Jiang; Yuhong Li; Chao Wang; Rong Zhang
Journal:  Front Oncol       Date:  2021-05-10       Impact factor: 6.244

10.  Differential gene expression identifies a transcriptional regulatory network involving ER-alpha and PITX1 in invasive epithelial ovarian cancer.

Authors:  Yichao Li; Sushil K Jaiswal; Rupleen Kaur; Dana Alsaadi; Xiaoyu Liang; Frank Drews; Julie A DeLoia; Thomas Krivak; Hanna M Petrykowska; Valer Gotea; Lonnie Welch; Laura Elnitski
Journal:  BMC Cancer       Date:  2021-07-03       Impact factor: 4.430

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.